Mathias joined Forbion in 2016. Before, he was project leader for metabolic disease therapy at the Max Planck Institute of Biochemistry (MPIB), managing international and multi-disciplinary drug discovery collaborations as well as supervising a research team to investigate GRK5 signaling in diabetes and cancer. Based on his scientific findings, which led to four patents, he gained a seed financing by GlaxoSmithKline and managed the scientific implementation of this joint venture on behalf of the MPIB. Supported by Prof. Dr. Axel Ullrich, the generated data provided the basis of spin-out activities within the field of type 2 diabetes, which Mathias accompanied as co-founder and CSO.

About Forbion – Forbion is a dedicated life sciences venture capital firm with offices in The Netherlands and Germany. We work closely together with entrepreneurs to support their technologies and products designed to transform people’s lives. For this purpose, we are backing innovative ideas not only with venture capital but also with our broad network as well as in-house expertise in drug development and company building. Forbion manages well over EUR 800 million across nine funds, currently invests out of its €183m FCFIII fund and is actively looking for innovative opportunities in the arena of pharmaceuticals, medical devices and diagnostics. For more information, please visit